接受治疗药物监测的HIV感染者用药负担与聚类分析
本研究基于治疗药物监测登记库,分析2432名参与者(含1158名HIV感染者)的多药治疗患病率、预测因素及药物类别聚类模式。结果显示对照组多药治疗患病率高于HIV感染者,高龄、女性及HIV阳性状态为多药治疗的独立预测因素,聚类分析揭示口服降糖药患者常联用多种其他药物,阿片类、利尿剂及中枢神经系统药物形成共药聚类。
要点
- HIV感染者多药治疗患病率26.1%,低于对照组的21.8%(P=.015)。
- 高龄、女性及HIV阳性状态是多药治疗的独立预测因素。
- 口服降糖药患者常联用多种其他药物,提示共病聚集及药物相互作用风险。
核心结论
- 中年HIV感染者中多药治疗患病率中等偏高,高龄和女性与最高患病率相关。
- 共药聚类提示共病分组,并识别出具有相似药物相互作用风险的患者群体。
研究设计与样本
- 基于治疗药物监测登记库的回顾性分析,纳入2016-2020年间至少记录一种药物的2432名参与者(1158名HIV感染者),年龄49.6岁(±14.4)。
- 将合并用药分为26个药物类别,多药治疗定义为同时使用≥5种非抗逆转录病毒/非抗结核药物,严重多药治疗定义为≥10种。
- 采用多变量二元逻辑回归分析多药治疗/严重多药治疗的预测因素,并对药物类别进行层次平均连锁聚类分析。
主要发现
- 对照组合并用药数量高于HIV感染者(4 vs 3.1,P<.001),多药治疗患病率也更高(26.1% vs 21.8%,P=.015)。
- 多变量分析显示,高龄、女性及HIV阳性状态(P=.015)是多药治疗的独立预测因素;高龄和纳入年份是严重多药治疗的独立预测因素。
- 聚类分析显示,使用口服降糖药治疗2型糖尿病的患者接受其他多种药物的概率较高;阿片类、利尿剂及影响中枢神经系统的药物形成共药聚类。
临床怎么用
- 对高龄、女性HIV感染者应加强用药审查,关注多药治疗及潜在药物相互作用。
- 口服降糖药患者及使用阿片类、利尿剂、中枢神经系统药物者需重点评估共病和相互作用风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: People living with HIV (PLWH) have a high burden of comorbidities and concomitant medication use. The aim of this study was to analyse the prevalence, predictors and patterns of polypharmacy (PP) in a large therapeutic drug monitoring (TDM) registry. METHODS: We searched our TDM registry and categorized co-medications into 26 drug classes. We included patients with at least one medication recorded: PP and severe polypharmacy (sPP) were defined as the concomitant use of ≥5 or ≥10 nonantiretroviral/nonantitubercular drugs. Multivariable binary logistic analysis were conducted for identifying PP/sPP predictors. A hierarchical average-linkage cluster analysis was performed among drug classes. RESULTS: We included 2432 participants (1158 PLWH) aged 49.6 years (± 14.4) in the 2016-2020 period. A higher number of concomitant medications (4 vs 3.1, P < .001) and a higher prevalence of PP (26.1% vs 21.8%, P = .015) were recorded in controls. At multivariable binary logistic analysis older age, female gender and HIV-positive serostatus (P = .015) were independent predictors of PP; older age and year of inclusion were independent predictors of sPP. Cluster analysis showed that patients receiving oral drug for type 2 diabetes have a high probability of receiving several other drugs; a cluster of co-medications was observed with opioids, diuretics and central nervous system-affecting drugs. CONCLUSION: We observed a moderately high prevalence of polypharmacy in middle-aged PLWH: advanced age and female gender were associated with the greatest prevalence. The observation of co-medication clusters suggests groups of comorbidities but also identifies groups of patients at risk of similar drug-to-drug interactions.
引用
- Calcagno A, de Nicolò A, Pizzi C, et al. Medication burden and clustering in people living with HIV undergoing therapeutic drug monitoring. Br J Clin Pharmacol. 2021. PMID: 33890312. doi:10.1111/bcp.14869
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。